Please assess the completion status of the following clinical trial:

Trial Title: Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed adenocarcinoma of the breast~* Tumor shows 3+ overexpression of the human epidermal growth factor receptor 2 (HER-2)/proto-oncogene by immunohistochemistry assay, or is fluorescence in situ hybridization (FISH)+~* Stage IV disease~* Measurable disease~* At least 3 weeks since prior cytotoxic chemotherapy~* At least 4 weeks since radiotherapy with full recovery~* At least 4 weeks since major surgery with full recovery~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* At least 18 years old~* Absolute neutrophil count (ANC) at least 1.5 x 10\^9 cells/L~* Platelets at least 100 x 10\^9 cells/L~* Hemoglobin at least 9 g/dL~* Aspartame aminotransferase (AST), alanine aminotransferase (ALT) less than 2.5X upper limit normal~* Alkaline Phosphatase less than 1.5X upper limit normal~* Creatinine less than 1.5 gm/dL~* Normal left ventricular ejection fraction~* Negative pregnancy test~* Agree to use method to avoid pregnancy~* Informed Consent is obtained~Exclusion Criteria:~* Up to one regimen of prior neo-adjuvant or adjuvant chemotherapy is allowed. One year since Taxane and Herceptin treatment.~* Cumulative life-time dose of doxorubicin is greater than 360 mg/m\^2~* Concurrent immunotherapy or hormonal therapy~* Parenchymal brain metastases, if present, must be documented to be clinically and radiographically stable for at least 6 months after treatment~* Serious intercurrent medical or psychiatric illness, including serious active infection~* History of congestive heart failure~* History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer~* Patients who have received an investigational drug within the previous 3 weeks~* Patient is currently enrolled in another clinical study receiving investigational therapies~* Pregnant or nursing women

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albumin-bound paclitaxel, Carboplatin + Herceptin (Type: EXPERIMENTAL): Participants received albumin-bound paclitaxel, 100 mg/m\^2 weekly every 3 out of 4 weeks, carboplatin at an area under the curve (AUC) = 6 every 4 weeks and Herceptin weekly, 4 mg/kg the first week and 2 mg/kg on all subsequent weeks by intravenous (IV) infusion for up to 6 cycles in the absence of disease progression or intolerable toxicity. Participants could continue treatment with chemotherapy beyond 6 cycles at the discretion of the investigator, but Herceptin therapy was to continue to be administered weekly (2 mg/kg) until intercurrent illness, disease progression, unacceptable toxicity, patient withdrawal or administration of any non-protocol anti-cancer treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).